Novartis-Alnylam deal produces revenue for Isis

09/13/2005 | Yahoo!

The recently announced Novartis partnership with Alnylam for the development of RNA interference drugs is expected to produce nearly $4 million for California-based Isis Pharmaceuticals. Isis said it is entitled to a share of the Novartis upfront payments to Alnylam as a result of the technology Isis had licensed to Alnylam.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA